255 related articles for article (PubMed ID: 2862253)
1. Disposition of HI-6 oxime in rats after intravenous and intramuscular administration.
Simons KJ; Briggs CJ
J Pharm Pharmacol; 1985 May; 37(5):367-9. PubMed ID: 2862253
[TBL] [Abstract][Full Text] [Related]
2. HI-6 pharmacokinetics in rabbits after intravenous and intramuscular administration.
Lukey BJ; Woodard CL; Clark CR; McCluskey MP
J Pharm Pharmacol; 1992 Aug; 44(8):690-2. PubMed ID: 1359099
[TBL] [Abstract][Full Text] [Related]
3. Bioavailability and disposition kinetics of HI-6 in Beagle dogs.
Baggot JD; Buckpitt A; Johnson D; Brennan P; Chung H
Biopharm Drug Dispos; 1993 Mar; 14(2):93-105. PubMed ID: 8453028
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics of HI-6 in beagle dogs.
Simons KJ; Briggs CJ
Biopharm Drug Dispos; 1983; 4(4):375-88. PubMed ID: 6661515
[TBL] [Abstract][Full Text] [Related]
5. Intravenous application of HI-6 salts (dichloride and dimethansulphonate) in pigs: comparison with pharmacokinetics profile after intramuscular administration.
Zdarova Karasova J; Zemek F; Kunes M; Kvetina J; Chladek J; Jun D; Bures J; Tachecí I; Kuca K
Neuro Endocrinol Lett; 2013; 34 Suppl 2():74-8. PubMed ID: 24362096
[TBL] [Abstract][Full Text] [Related]
6. Rapid and equivalent systemic bioavailability of the antidotes HI-6 and dicobalt edetate via the intraosseous and intravenous routes.
Hill SL; Thomas SH; Flecknell PA; Thomas AA; Morris CM; Henderson D; Dunn M; Blain PG
Emerg Med J; 2015 Aug; 32(8):626-31. PubMed ID: 25414476
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of the oximes HI 6 and HLö 7 in dogs after i.m. injection with newly developed dry/wet autoinjectors.
Spöhrer U; Thiermann H; Klimmek R; Eyer P
Arch Toxicol; 1994; 68(8):480-9. PubMed ID: 7802588
[TBL] [Abstract][Full Text] [Related]
8. Trimedoxime and HI-6: kinetic comparison after intravenous administration to mice.
Milic B; Maksimovic M; Nedelijkovic M
Pharmacol Toxicol; 1996 Apr; 78(4):269-72. PubMed ID: 8861786
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and toxicity of the oxime HGG 12 in dogs.
Klimmek R; Eyer P
Arch Toxicol; 1985 Sep; 57(4):237-42. PubMed ID: 4091648
[TBL] [Abstract][Full Text] [Related]
10. The acetylcholinesterase oxime reactivator HI-6 in man: pharmacokinetics and tolerability in combination with atropine.
Clement JG; Bailey DG; Madill HD; Tran LT; Spence JD
Biopharm Drug Dispos; 1995 Jul; 16(5):415-25. PubMed ID: 8527690
[TBL] [Abstract][Full Text] [Related]
11. Oral kinetics and bioavailability of the cholinesterase reactivator HI-6 after administration of 2 different formulations of tablets to dogs.
Maksimović M; Jovanović D; Kovacević V; Bokonjić D
Toxicol Lett; 1987 Nov; 39(1):85-91. PubMed ID: 3672559
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of HI-6 and atropine in anaesthetized pigs after administration by a new autoinjector.
Nyberg AG; Cassel G; Jeneskog T; Karlsson L; Larsson R; Lundström M; Palmer L; Persson SA
Biopharm Drug Dispos; 1995 Nov; 16(8):635-51. PubMed ID: 8573684
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of atropine in dogs after i.m. injection with newly developed dry/wet combination autoinjectors containing HI 6 or HLö 7.
Thiermann H; Radtke M; Spöhrer U; Klimmek R; Eyer P
Arch Toxicol; 1996; 70(5):293-9. PubMed ID: 8852700
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the reactivating and therapeutic efficacy of two novel bispyridinium oximes (K727, K733) with the oxime HI-6 and obidoxime in sarin-poisoned rats and mice.
Kassa J; Sepsova V; Matouskova L; Horova A; Musilek K
Toxicol Mech Methods; 2015 Mar; 25(3):229-33. PubMed ID: 25894563
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of therapeutic and reactivating effects of newly developed oximes (K156, K203) and commonly used oximes (obidoxime, trimedoxime, HI-6) in tabun-poisoned rats and mice.
Kassa J; Karasova J; Musilek K; Kuca K
Toxicology; 2008 Jan; 243(3):311-6. PubMed ID: 18054821
[TBL] [Abstract][Full Text] [Related]
16. HI-6 and 2-PAM in sheep: pharmacokinetics and effects on muscle tissue following intramuscular injection.
Moore DH; Hayward IJ; Tucker FS; Lukey B
Biopharm Drug Dispos; 1991 Apr; 12(3):223-32. PubMed ID: 2059672
[TBL] [Abstract][Full Text] [Related]
17. Kinetic profile in blood and brain of the cholinesterase reactivating oxime HI-6 after intravenous administration to the rat.
Ligtenstein DA; Kossen SP
Toxicol Appl Pharmacol; 1983 Nov; 71(2):177-83. PubMed ID: 6636183
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of single doses of cefoperazone given by the intravenous and intramuscular routes to unweaned calves.
Soback S; Ziv G
Res Vet Sci; 1989 Sep; 47(2):158-63. PubMed ID: 2799072
[TBL] [Abstract][Full Text] [Related]
19. [Studies on the metabolic fate of isepamicin sulfate (HAPA-B). I. Absorption, distribution, metabolism and excretion in rats].
Suzuki T; Serizawa K; Somiya Y; Shirai M; Endo S; Morishita M
Jpn J Antibiot; 1987 Jan; 40(1):188-201. PubMed ID: 3586328
[TBL] [Abstract][Full Text] [Related]
20. Formation of cyanide after i.v. administration of the oxime HI 6 to dogs.
Eyer P; Kawan A; Ladstetter B
Arch Toxicol; 1987; 61(1):63-9. PubMed ID: 3439876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
